Vaccines and antibiotic resistance

Identification of novel vaccine candidates againstAcinetobacter baumanniiusing reverse vaccinology

“…[1][2][3][4][5][6] Ab can stick to dry surfaces for a long time especially in hospital intensive care units through ventilator-associated machine and biotic surfaces. Ab accounts for >7,000 hospital-acquired infections (HAI) and over 500 deaths per year in the United States only.…”

“…Ab accounts for >7,000 hospital-acquired infections (HAI) and over 500 deaths per year in the United States only. 3 Since the numbers of multi-drug resistant (MDR) and pan-drug resistant (PDR) strains are increasing, [3][4][5][6] prevention and treatment of Ab infections have become a significant health care challenge and new strategies against Ab infections are urgently needed. In the absence of efficacious and safe antibiotics, vaccination represents the best strategy to combat MDR pathogens.…”

“…In the absence of efficacious and safe antibiotics, vaccination represents the best strategy to combat MDR pathogens. 6,7 So far, several potential Ab antigens have been identified through active and passive immunizations of experimental animals. They include outer membrane vesicles (OMVs), outer membrane protein A (OmpA), auto-transporter (Ata), biofilm-associated protein (Bap), K1 capsular polysaccharide and Poly-N-acetyl-b-(1-6)-glucosamine (PNAG).…”

“…6,[15][16][17] RV integrates comparative analysis of genome sequences and web-based prediction tools for screening highly conserved outer-membrane proteins and soluble secreted proteins. Meningococcal group B vaccine (4CMenB) serves as an example of a successful RV approach.…”

Vaccination to Combat as an Approach to Reduce the Antibacterial Resistance..!

“…Unlike antibiotics, there have been no reports on bacterial resistance to vaccines. Vaccines also does not exert massive selective pressure on the environment [27]. However, those serotypes not covered by the vaccines could spread at a higher rate such as the seven-valent pneumococcal conjugate vaccine (PCV7) against Streptococcus pneumonia [28][29][30].The advent of the omics field has given rise to vaccinomics [31,32] which is based on high throughput Next Generation Sequencing (NGS) and robust bioinformatics pipelines technologies.…”